TG Therapeutics, Inc. Initiates a Phase I/II Clinical Trial of Its Novel Third-Generation Anti-CD20 Monoclonal Antibody, TG-1101 (Ublituximab), in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies

Published: Dec 07, 2012

NEW YORK, Dec. 7, 2012 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (OTCBB:TGTX) today announced that it has initiated a Phase I/II trial to evaluate the safety, tolerability and efficacy of TG-1101, the company's novel third-generation anti-CD20 monoclonal antibody, in combination with lenalidomide (Revlimid®) for patients with relapsed or refractory B-cell lymphoid malignancies who were previously treated with anti-CD20 antibody therapy. This multicenter trial will be led by Dr. Marshall Schreeder of the Clearview Cancer Institute in Huntsville, AL. This marks the company's second clinical trial of TG-1101 in North America, following the initiation of the Company's on-going Phase I/II trial with single agent TG-1101 in patients with Non-Hodgkin's Lymphoma (NHL), which opened for enrollment in September of this year. These studies build upon the Company's first in man clinical trial reported last year at ASH in which TG-1101 was studied in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). In that study, which was presented at the 53rd Annual American Society of Hematology meeting in December 2011, TG-1101 demonstrated a 45% ORR.

Back to news